MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Amiloride hydrochloride

CAS No. : 2016-88-8

MCE 国际站：Amiloride hydrochloride

产品活性：Amiloride hydrochloride (MK-870 hydrochloride) 是上皮钠通道 (ENaC) 和尿激酶型纤溶酶原激活物受体 (uTPA) 的抑制剂。Amiloride hydrochloride 是 polycystin-2 (PC2; TRPP2) 通道阻断剂。

研究领域：Membrane Transporter/Ion Channel | Neuronal Signaling | Apoptosis

作用靶点：Sodium Channel | TRP Channel | Apoptosis

In Vitro: Amiloride blocks δβγ channels with an IC₅₀ of 2.6 µM. The K_i of amiloride for δβγ ENaC is 26-fold that of αβγ channels (0.1 µM for αβγ ENaC). Amiloride blockade of δβγ ENaC is much more voltage dependent compared with the αβγ channel. The K_i of amiloride for δαβγ channels is 920 and 13.7 µM at −120 and ⁺80 mV, respectively, which significantly differs from that of both αβγ and δβγ channels. Amiloride is a relatively selective inhibitor of the epithelial sodium channel (ENaC) with an IC₅₀ (the concentration required to reach 50% inhibition of an ion channel) in the concentration range of 0.1 to 0.5 µM. Amiloride is a relatively poor inhibitor of the the Na⁺/H⁺ exchanger (NHE) with an IC₅₀ as low as 3 µM in the presence of a low external [Na⁺] but as high as 1 mM in the presence of a high [Na⁺]. Amiloride is an even weaker inhibitor of the Na⁺/Ca²⁺ exchanger (NCX), with an IC₅₀ of 1 mM. Amiloride (1 µM) and submicromolar doses of Benzamil (30 nM), doses known to inhibit the ENaC, inhibit the myogenic vasoconstriction response to increasing perfusion pressure by blocking the activity of ENaC proteins. Amiloride completely inhibits Na⁺ influx in doses known to be relatively specific for ENaC (1.5 µM) in vascular smooth muscle cells (VSMC).

In Vivo: Amiloride (1 mg/kg/day) subcutaneously is found to reverse the initial increases in collagen deposition and prevent any further increases in the DOCA-salt hypertensive rat. Amiloride delays the onset of proteinuria and improved brain and kidney histologic scores in the saline-drinking, stroke-prone spontaneously hypertensive rats (SHRSP) compared with controls. Amiloride antagonizes or prevents actions of aldosterone in these cells and in cardiovascular and renal tissues in animals with salt-dependent forms of hypertension.

相关产品：Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Apoptosis Compound Library | Kinase Inhibitor Library | Membrane Transporter/Ion Channel Compound Library | Neuronal Signaling Compound Library | FDA-Approved Drug Library | Drug Repurposing Compound Library | Anti-Cardiovascular Disease Compound Library | Anti-COVID-19 Compound Library | NMPA-Approved Drug Library | Orally Active Compound Library | FDA Approved & Pharmacopeial Drug Library | Neuroprotective Compound Library | Drug-Induced Liver Injury (DILI) Compound Library | MG-132 | LY294002 | Doxorubicin hydrochloride | Bafilomycin A1 | Paclitaxel | Y-27632 dihydrochloride | Acetylcysteine | Angiotensin II human | SP600125 | 5-Fluorouracil | Staurosporine | Bortezomib | Tamoxifen | 2-Deoxy-D-glucose | Gemcitabine | Verteporfin | Decitabine | Actinomycin D | Temozolomide | BAY 11⁻⁷082 | Etoposide | Mitomycin C | CCCP | DAPT | Rotenone | Etomoxir | Stattic | Docetaxel | Fulvestrant

品牌介绍:
• MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；
• 10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
• 设有专业的实验中心和严格的质控、验证体系；
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
• 产品的生物活性多经各国客户实验验证；
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
• 专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
• 与世界各大制药公司及知名科研机构建立了长期的合作。